valbenazine
valbenazine: sourced relationships with 1 company · 9 clinical trials tracked · 1 FDA decision.
valbenazine evidence translation
What we can confirm
1 FDA record · 9 tracked trials
What it means
What to watch
Prepared research question
How could valbenazine → TEVA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 1 study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) Reported 2026-01-21 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (9)
Valbenazine in Obsessive-compulsive Disorder: A Randomized Double-blind Placebo-controlled Crossover Trial
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Primary endpoint: Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24
Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
Primary endpoint: Change in demoralization Scale
Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada
Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study to Assess the Safety, Tolerability, and Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
Primary endpoint: Change in Massachusetts General Hospital Hairpulling Scale (MGH-HPS) from baseline to Week 12
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia
Primary endpoint: Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Primary endpoint: Change in the Total Maximal Chorea (TMC) Score of the Unified Huntington Disease Rating Scale (UHDRS) from Baseline to the Average of the Week 12 and Week 14 assessments
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Primary endpoint: Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 10
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Frequently asked questions
Which companies have sourced relationships with valbenazine?
valbenazine has dated SEC/FDA relationship records for Teva Pharmaceutical Industries Limited.
How many clinical trials involve valbenazine?
BioSniper tracks 9 clinical trials involving valbenazine.
What is valbenazine's latest FDA decision?
The most recent tracked FDA decision for valbenazine is Tentative Approval, dated January 21, 2026.